We are live on ! Find out more
IMUC.WS

ImmunoCellular Therapeutics Ltd.
IMUC.WS

Delisted

IMUC.WS was delisted on the 16th of October, 2018.

Back to rankings

3 hedge funds and large institutions have $31K invested in ImmunoCellular Therapeutics Ltd. in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding

Funds holding: 1 → 3 (+2)

7% more capital invested

Capital invested by funds: $29K → $31K (+$2K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$1.72K
2
UBS Group
UBS Group
Switzerland
+$2

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
1
Anson Funds Management
Texas
$30K – -1 -0%
SM
2
Sabby Management
Florida
$1K +$1.72K +74,443 New
UBS Group
3
UBS Group
Switzerland
– +$2 +100 New

IMUC.WS Hedge Fund Activity: Q2 2018 in Review

3 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q2 2018, worth a combined $31K — up 6.9% from $29K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new IMUC.WS positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $1.72K.

  • 3 institutional investors held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q2 2018, up from 1 in Q1 2018.
  • Funds reported $31K of ImmunoCellular Therapeutics Ltd. stock for Q2 2018, up 6.9% quarter-over-quarter.
  • 2 funds opened new ImmunoCellular Therapeutics Ltd. positions in Q2 2018 and 0 closed out, a net change of +2 holders.
  • The largest ImmunoCellular Therapeutics Ltd. buyer in Q2 2018 was Sabby Management, an estimated $1.72K added.

Based on aggregated 13F filings for Q2 2018.